Stocktoria
PROTHENA CORP PUBLIC LTD CO PRTA
PROTHENA CORP PUBLIC LTD CO (PRTA) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $9.7M at a -2520.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.839 |
| Retained earnings / assets | -4.12 |
| EBIT / assets | -0.657 |
| Equity / liabilities | 6.054 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PRTA | PROTHENA CORP PUBLIC LTD CO | 1/9 | -5.98 | — | -92.8% |
| PGEN | PRECIGEN, INC. | 2/9 | — | — | — |
| JANX | Janux Therapeutics, Inc. | 2/9 | — | — | -5.6% |
| CBIO | CRESCENT BIOPHARMA, INC. | 4/9 | 4.59 | — | — |
| ROIV | Roivant Sciences Ltd. | 1/9 | 18.07 | — | -71.6% |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
About PROTHENA CORP PUBLIC LTD CO
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
FAQ
Is PRTA financially healthy?
PROTHENA CORP PUBLIC LTD CO's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PRTA pay a dividend?
No, PROTHENA CORP PUBLIC LTD CO does not currently pay a dividend.
How profitable is PRTA?
In FY2025, PROTHENA CORP PUBLIC LTD CO had a net margin of -2520.6% and a return on equity of -87.0%.
What is the analyst price target for PRTA?
The average Wall-Street price target for PROTHENA CORP PUBLIC LTD CO is $21.40, about 131.1% above the recent price, from 5 analysts.
Is PRTA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PROTHENA CORP PUBLIC LTD CO: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.